


Apararenone

Cat. No.:	HY-109002		
CAS No.:	945966-46-1		
Molecular Formula:	C ₁₇ H ₁₇ FN ₂ O ₄ S		
Molecular Weight:	364.39		
Target:	Mineralocorticoid Receptor		
Pathway:	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 125 mg/mL (343.04 mM)
 * "≥" means soluble, but saturation unknown.

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.7443 mL	13.7216 mL	27.4431 mL
5 mM	0.5489 mL	2.7443 mL	5.4886 mL
10 mM	0.2744 mL	1.3722 mL	2.7443 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Apararenone (MT-3995) is a novel non-steroidal mineralocorticoid receptor antagonists under development for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis.

IC₅₀ & Target

Mineralocorticoid receptor^[1]

In Vivo

Recently, a phase II clinical trial has been initiated among patients with non-alcoholic steatohepatitis (NASH) in Japan^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Kolkhof P, et al. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017 Jul;234(1):T125-T140.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA